Zimmer issues first growth forecasts:
This article was originally published in Clinica
Zimmer expects its first 18 months as an independent company to generate sales growth of between 8-11% and income after separation costs to grow by 11-14%. Zimmer predicts growth in North and South America to be above its overall increase, but that Europe and Asia Pacific will be below the average rate. Reconstructive implants are set to grow by 10-13%, while fracture management product sales will go up by 6-9%. Zimmer is set to begin trading independently on August 7 following its previously announced spin-off from Bristol-Myers Squibb.